Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 13/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 13/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 13/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217514 | 0.85 | GABRA1 (0.33) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL5768555 | 0.85 | GABRA1 (0.33) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL5770463 | 0.81 | ALDH1A1 (0.36) | KDM4ENPC1ALDH1A1GAARAB9A | |
| SCHEMBL5769993 | 0.78 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL5771081 | 0.77 | KDM4E (0.34) | GABRA1GABRG2GABRB3KDM4ENPC1 | |
| SCHEMBL5770695 | 0.74 | JAK2 (0.36) | — | |
| SCHEMBL6218809 | 0.74 | HMGCR (0.32) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL16346664 | 0.72 | ALDH1A1 (0.49) | GABRA1GABRG2GABRB3GABRA3KDM4E | |
| SCHEMBL2015143 | 0.72 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL12469686 | 0.70 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605393-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024083773-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-25 | — | — | WO | disclosed |
| EP-4107159-A1 | 5-(3-(ETHYLSULFONYL)PYRIDIN-2-YL)-PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDE AND INSECTICIDE AGENTS FOR CROP PROTECTION | PI Industries Ltd. (IN) | 2022-12-28 | — | — | EP | disclosed |
| US-11229208-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| US-10939682-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-09 | — | — | US | disclosed |
| US-20210037827-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-11 | — | — | US | disclosed |
| US-20160255837-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-09-08 | — | — | US | disclosed |
| EP-3016949-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | Syngenta Participations AG (CH) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015000715-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-01-08 | — | — | WO | disclosed |
| EP-1451161-B1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME (GB) | 2007-04-18 | — | — | EP | disclosed |
| EP-1383768-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-09-06 | — | — | EP | disclosed |
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | BETTATI MICHELA | 2006-02-23 | — | — | US | disclosed |
| EP-1381606-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6642229-B2 | Treatment of adverse neurological conditions | MERCK SHARP & DOHME LTD. | 2003-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160255837-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | DDT, TST, SCLY | GABRA1 426/4885GABRG2 494/4885GABRB3 160/4885 |
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | CHRNA3, GABRA3, GABRB3 | GABRA1 8/4885GABRG2 61/4885GABRB3 3/4885 |
| US-20210037827-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | GSTA1, CYP1B1, DDT | GABRA1 972/4885GABRG2 2133/4885GABRB3 1054/4885 |
| US-10939682-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | DDT, TST, SCLY | GABRA1 426/4885GABRG2 494/4885GABRB3 160/4885 |
| US-11229208-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | GSTA1, CYP1B1, DDT | GABRA1 972/4885GABRG2 2133/4885GABRB3 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.